11:00 AM EDT, 07/01/2025 (MT Newswires) -- Femasys ( FEMY ) said Tuesday it received regulatory approvals in Australia and New Zealand for FemaSeed as a first-line intratubal insemination treatment and FemVue as a diagnostic evaluation.

The shares were more than 2% lower in recent trading.

Price: 0.94, Change: -0.03, Percent Change: -2.69